-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager Therapeutics To Present Eight Oral And Poster Studies At ASGCT 2026, Including Late‑Breaking GLP Toxicology Data On Investigational Tau‑Silencing Alzheimer's Gene Therapy VY1706 Ahead Of Planned IND Filing In Q2 And First‑In‑Human Dosing In H2 2026

Benzinga·04/27/2026 20:37:23
Listen to the news

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -

- Additional data demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability -

LEXINGTON, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced eight oral and poster presentations at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting taking place in Boston, May 11-15, 2026. Voyager's investigational tau-silencing gene therapy VY1706 for Alzheimer's disease, for which Voyager anticipates submitting an investigational new drug (IND) application in Q2 2026 to support projected first-in-human dosing in the second half of 2026, will be featured in a late-breaking presentation of three-month good laboratory practice (GLP) toxicology data.